Insights into Healthcare Professionals' Perceptions and Attitudes toward Nanotechnological Device Application: What Is the Current Situation in Glioblastoma Research?

attitudes awareness bias brain tumor cancer gliomas healthcare professionals nanotechnology psychology

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
28 Jun 2023
Historique:
received: 14 05 2023
revised: 14 06 2023
accepted: 21 06 2023
medline: 29 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

Nanotechnology application in cancer treatment is promising and is likely to quickly spread worldwide in the near future. To date, most scientific studies on nanomaterial development have focused on deepening the attitudes of end users and experts, leaving clinical practice implications unexplored. Neuro-oncology might be a promising field for the application of nanotechnologies, especially for malignant brain tumors with a low-survival rate such as glioblastoma (GBM). As to improving patients' quality of life and life expectancy, innovative treatments are worth being explored. Indeed, it is important to explore clinicians' intention to use experimental technologies in clinical practice. In the present study, we conducted an exploratory review of the literature about healthcare workers' knowledge and personal opinions toward nanomedicine. Our search (i) gives evidence for disagreement between self-reported and factual knowledge about nanomedicine and (ii) suggests the internet and television as main sources of information about current trends in nanomedicine applications, over scientific journals and formal education. Current models of risk assessment suggest time-saving cognitive and affective shortcuts, i.e., heuristics support both laypeople and experts in the decision-making process under uncertainty, whereas they might be a source of error. Whether the knowledge is poor, heuristics are more likely to occur and thus clinicians' opinions and perspectives toward new technologies might be biased.

Identifiants

pubmed: 37509494
pii: biomedicines11071854
doi: 10.3390/biomedicines11071854
pmc: PMC10376482
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : EURONANOMED
ID : 2019-075

Références

Curr Med Chem. 2017;24(27):3002-3009
pubmed: 28521700
J Neurooncol. 2014 Jul;118(3):489-99
pubmed: 24728785
Lancet Oncol. 2019 Jan;20(1):110-119
pubmed: 30522967
Curr Top Med Chem. 2021;21(15):1360-1376
pubmed: 34218784
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Curr Oncol Rep. 2012 Feb;14(1):48-54
pubmed: 22012633
J Drugs Dermatol. 2011 Sep;10(9):1037-41
pubmed: 22052274
Neuro Oncol. 2014 Jul;16(7):896-913
pubmed: 24842956
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Oncology (Williston Park). 2019 Mar 13;33(3):91-100
pubmed: 30866031
J Cancer. 2019 Oct 15;10(24):6175-6184
pubmed: 31762828
Biomed Res Int. 2015;2015:620643
pubmed: 25815327
Handb Clin Neurol. 2016;134:381-97
pubmed: 26948367
Adv Drug Deliv Rev. 2021 Apr;171:108-138
pubmed: 33486006
CA Cancer J Clin. 2020 Jul;70(4):299-312
pubmed: 32478924
Acta Anaesthesiol Scand. 2009 Feb;53(2):143-51
pubmed: 19032571
Neuro Oncol. 2016 Apr;18(4):549-56
pubmed: 26823503
Med Sci Educ. 2019 Oct 20;30(1):179-186
pubmed: 34457657
J Nanopart Res. 2014;16:2153
pubmed: 24482607
Int J Nanomedicine. 2014 Dec 15;9 Suppl 2:11-20
pubmed: 25565822
Pharmacol Res. 2021 Sep;171:105780
pubmed: 34302977
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Transl Neurosci. 2022 Dec 31;13(1):527-546
pubmed: 36741545
Curr Drug Metab. 2019;20(6):416-429
pubmed: 30227814
Acta Odontol Scand. 2020 Mar;78(2):152-160
pubmed: 31561718
Neuro Oncol. 2014 Jan;16(1):113-22
pubmed: 24285550
J Neurosurg. 2021 Jun 04;136(1):1-8
pubmed: 34087795
Environ Health Perspect. 2014 Oct;122(10):A276-9
pubmed: 25272337
J Pers Med. 2022 Jan 20;12(2):
pubmed: 35207625
BMJ Open. 2019 Sep 12;9(9):e028280
pubmed: 31515415
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
N Engl J Med. 2017 Nov 16;377(20):1954-1963
pubmed: 29141164
Regul Toxicol Pharmacol. 2021 Jun;122:104885
pubmed: 33617940
Science. 1974 Sep 27;185(4157):1124-31
pubmed: 17835457
Cancers (Basel). 2019 Nov 04;11(11):
pubmed: 31689995
J Neurooncol. 2020 Nov;150(2):215-267
pubmed: 33215344
J Glob Oncol. 2015 Oct 28;1(2):57-64
pubmed: 28804774
J Neurooncol. 2008 Sep;89(3):313-37
pubmed: 18712283
Implement Sci Commun. 2023 Feb 10;4(1):13
pubmed: 36765402
Brain Sci. 2022 May 16;12(5):
pubmed: 35625037
Front Oncol. 2015 Jan 29;5:12
pubmed: 25688335
JBI Database System Rev Implement Rep. 2017 Nov;15(11):2723-2788
pubmed: 29135752
Eur J Oral Sci. 2021 Dec;129(6):e12821
pubmed: 34729822
Pharmacy (Basel). 2022 Jan 21;10(1):
pubmed: 35202067
Neuro Oncol. 2018 Jan 22;20(2):184-191
pubmed: 29016900
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Continuum (Minneap Minn). 2020 Dec;26(6):1452-1475
pubmed: 33273168
Front Bioeng Biotechnol. 2022 Feb 09;10:801822
pubmed: 35223783

Auteurs

Federica Ragucci (F)

Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Francesca Sireci (F)

Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Francesco Cavallieri (F)

Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Jessica Rossi (J)

Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Giuseppe Biagini (G)

Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Giovanni Tosi (G)

Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Chiara Lucchi (C)

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Rodolfo Molina-Pena (R)

Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, 49000 Angers, France.

Natalia Helen Ferreira (NH)

Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, 49000 Angers, France.

Mariana Zarur (M)

Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.

Alba Ferreiros (A)

Nasasbiotech, S.L., Canton Grande 9, 15003 A Coruña, Spain.

William Bourgeois (W)

Braintech Lab, INSERM Unit 1205, Grenoble Alpes University, 38000 Grenoble, France.

François Berger (F)

Braintech Lab, INSERM Unit 1205, Grenoble Alpes University, 38000 Grenoble, France.

Miguel Abal (M)

Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain.

Audrey Rousseau (A)

Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, 49000 Angers, France.
Département de Pathologie, CHU d'Angers, CRCINA Université de Nantes, 49933 Angers, France.
Département de Pathologie, CHU d'Angers, Université d'Angers, 49933 Angers, France.

Frank Boury (F)

Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, 49000 Angers, France.

Carmen Alvarez-Lorenzo (C)

Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.

Emmanuel Garcion (E)

Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, 49000 Angers, France.

Anna Pisanello (A)

Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Giacomo Pavesi (G)

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Corrado Iaccarino (C)

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Luca Ghirotto (L)

Qualitative Research Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Maria Chiara Bassi (MC)

Medical Library, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Franco Valzania (F)

Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Classifications MeSH